Insiders who reported open-market trades in the last 12 months at the companies James B. Tananbaum files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
James B. Tananbaum is a corporate insider, tracked as Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has James B. Tananbaum submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has James B. Tananbaum been buying or selling stock?
Recorded transactions: 6 open-market purchases ($6.15M) and 0 open-market sales across all tracked filings.
James B. Tananbaum is Director, 10% Owner of Latigo Biotherapeutics, Inc. (LTGO). 4 SEC Form 4 filings on record going back to 2025, most recently on 11 August 2026. Most recent open-market trade: bought $2.52M of LTGO on 11 August 2026. Lifetime open-market purchases: $6.15M.
Recent transactions
17
The latest 17 SEC Form 4 transactions reported by James B. Tananbaum.
InsiderAlpha's records for James B. Tananbaum go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $1.02M (6 buys totaling $6.15M). The largest single buy on record is $2.52M of LTGO in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
